Replimune Group (NASDAQ:REPL) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Replimune Group (NASDAQ:REPL) released its earnings results on Tuesday. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07, Zacks reports.

Replimune Group Stock Performance

REPL stock traded down $0.26 during midday trading on Wednesday, reaching $11.93. The stock had a trading volume of 132,344 shares, compared to its average volume of 1,036,191. The stock has a market cap of $815.06 million, a PE ratio of -3.91 and a beta of 1.19. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46. The firm has a fifty day simple moving average of $11.42 and a two-hundred day simple moving average of $9.49. Replimune Group has a 52-week low of $4.92 and a 52-week high of $12.97.

Insider Buying and Selling at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now directly owns 101,057 shares in the company, valued at $1,028,760.26. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on REPL. JPMorgan Chase & Co. upped their price target on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research report on Tuesday. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, Roth Mkm assumed coverage on Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $16.80.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.